Filtered By:
Specialty: Pharmaceuticals
Condition: Heart Disease
This page shows you your search results in order of date.
Order by Relevance | Date
Total 69 results found since Jan 2013.
The Questions We Should Now Ask After Drug Maker States Wegovy Decreases Risk Of Heart Issues
Given the obesity epidemic in America, these results could have profound public health consequences for Americans in helping to curb rates of heart disease and stroke.
Source: Forbes.com Healthcare News - September 6, 2023 Category: Pharmaceuticals Authors: Omer Awan, Contributor Tags: Healthcare /healthcare Innovation /innovation standard Source Type: news
Why You Should Pay Attention To Diabetes
This means that more than 1 in 3 Americans has prediabetes, which is more than the number of Americans that have cancer, heart disease, or stroke.
Source: Forbes.com Healthcare News - June 1, 2023 Category: Pharmaceuticals Authors: Omer Awan, Contributor Tags: Healthcare /healthcare Innovation /innovation standard Source Type: news
ERLEADA ® (apalutamide), First-and-Only Next-Generation Androgen Receptor Inhibitor with Once-Daily, Single-Tablet Option, Now Available in the U.S.
HORSHAM, Pa., April 3, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the availability of an additional tablet strength of ERLEADA® (apalutamide) in the United States. The introduction of the 240mg tablet provides the first-and-only option for a once-daily, single-tablet Androgen Receptor Inhibitor (ARI) approved for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).With two strengths available, healthcare professionals will have the flexibility to...
Source: Johnson and Johnson - April 3, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO ® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)
TITUSVILLE, NJ, March 5, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) over standard of care (aspirin alone), demonstrating consistent benefit at 30 days, 90 days and up to three years following LER in patients with PAD. Lower extremity revascularization, also called peripheral revascularization, is a procedure that restores blood flow in blocked arteries or veins. This analysis of ...
Source: Johnson and Johnson - March 5, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Pioglitazone Use Linked to Reduced Dementia Risk in T2DM
THURSDAY, Feb. 16, 2023 -- For patients with diabetes mellitus (DM), pioglitazone use is associated with a reduced risk for dementia, especially in those with a history of ischemic heart disease or stroke, according to a study published online Feb....
Source: Drugs.com - Pharma News - February 16, 2023 Category: Pharmaceuticals Source Type: news
Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Has The Obesity Epidemic Gotten Out Of Hand In America?
Obesity is linked to a number of health ailments, including diabetes, heart disease, stroke, and a number of cancers such as breast and colorectal. If that wasn ’t enough, the annual medical cost of obesity was nearly 173 billion dollars in 2019 alone.
Source: Forbes.com Healthcare News - January 25, 2023 Category: Pharmaceuticals Authors: Omer Awan, Contributor Tags: Healthcare /healthcare Innovation /innovation Source Type: news
America ’s Obsession With Alcohol- Will It Ever End?
Alcohol use, even at moderate amounts, is linked to a number of medical and health-related issues; including but not limited to an increase risk of cancers such as liver, esophagus, and breast; an increased risk of heart disease, stroke, and high blood pressure.
Source: Forbes.com Healthcare News - January 18, 2023 Category: Pharmaceuticals Authors: Omer Awan, Contributor Tags: Healthcare /healthcare Innovation /innovation Source Type: news
Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
IHD, Stroke Risk Up for Offspring Born to Moms With Preeclampsia
THURSDAY, Nov. 17, 2022 -- Offspring born to individuals with preeclampsia have an increased risk for ischemic heart disease (IHD) and stroke, according to a study published online Nov. 15 in JAMA Network Open.
Fen Yang, M.D., from the Karolinska...
Source: Drugs.com - Pharma News - November 17, 2022 Category: Pharmaceuticals Source Type: news
Janssen ’s Save Legs. Change Lives.™ is Creating a More Equitable Future for Communities at Risk of PAD-Related Amputations
TITUSVILLE, NJ, November 4, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the first impact summary for its Save Legs. Change Lives.™ Spot Peripheral Artery Disease Now multi-year initiative, designed to create urgency and action around the hidden threat of peripheral artery disease (PAD)-related amputation. In its inaugural year, Save Legs. Change Lives.™ focused on reaching Black Americans, who are up to four times more likely than white Americans to have a PAD-related amputation.1 With this critical initiative, Janssen is focused on helping those at risk of PAD through more th...
Source: Johnson and Johnson - November 4, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Apixaban Compared to Rivaroxaban for A-Fib and Valvular Heart Disease
WEDNESDAY, Oct. 19, 2022 -- For patients with atrial fibrillation (AF) and valvular heart disease (VHD), apixaban is associated with a reduced risk for ischemic stroke or systemic embolism and a reduced risk for bleeding compared with rivaroxaban,...
Source: Drugs.com - Pharma News - October 19, 2022 Category: Pharmaceuticals Source Type: news
Survey: Noncommunicable Diseases Still Underestimated, Only 59% View Diabetes As Very Harmful
Gallup also found that of those interviewed only 83% considered cancer, 72% considered heart disease and stroke, and 51% considered lung disease to be "very harmful. ”
Source: Forbes.com Healthcare News - October 17, 2022 Category: Pharmaceuticals Authors: Bruce Y. Lee, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation Business /business Food & Drink /food-drink pharma Source Type: news
Biosense Webster Launches the OCTARAY ™ Mapping Catheter with TRUEref™ Technology
IRVINE, CA – September 6, 2022 – Biosense Webster, Inc., part of Johnson & Johnson MedTech[†], today announced the release of the OCTARAY™ Mapping Catheter with TRUEref™ Technology powered by the CARTO™ 3 Version 7 System. The OCTARAY™ Mapping Catheter was developed for the mapping of cardiac arrhythmias, including atrial fibrillation (AFib). The catheter has eight splines with improved electrode spacing options to provide shorter and more efficient mapping times than PENTARAYTM NAV ECO Mapping Catheter, which may shorten overall ablation procedure times.[2],[8],[‡] AFib is the most common type of cardi...
Source: Johnson and Johnson - September 6, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news
